-transparent.png){kind=logo}
Plasma adenosine deaminase2 (ADA2) has recently been proposed to be a marker for human immunodeficiency virus-1 (HIV) infection. We measured ADA2 levels in plasma from two groups of white homosexual males at 6-month intervals for a total of 2.5 years. One group consisted of 6 subjects who seroconverted for HIV, and the other consisted of 8 HIV seropositive patients who progressed from asymptomatic (CDC Groups II/III) to symptomatic (CDC Group IV) disease. Seroconversion was associated with a significant increase in plasma ADA2 which persisted throughout follow-up of 1.5 years. However, disease progression in HIV seropositive patients was not associated with any significant change in plasma ADA2. In conclusion, ADA2 may represent a unique marker for HIV seroconversion which does not change with later progression to symptomatic disease.
J G Niedzwicki, and
K H Mayer, and
E Abushanab, and
D R Abernethy
January 1992,
International journal of STD & AIDS,
J G Niedzwicki, and
K H Mayer, and
E Abushanab, and
D R Abernethy
June 1998,
International journal of dermatology,
J G Niedzwicki, and
K H Mayer, and
E Abushanab, and
D R Abernethy
August 1994,
The Journal of infectious diseases,
J G Niedzwicki, and
K H Mayer, and
E Abushanab, and
D R Abernethy
January 1990,
Research in virology,
J G Niedzwicki, and
K H Mayer, and
E Abushanab, and
D R Abernethy
June 1992,
American journal of ophthalmology,
J G Niedzwicki, and
K H Mayer, and
E Abushanab, and
D R Abernethy
October 1991,
Blood,
J G Niedzwicki, and
K H Mayer, and
E Abushanab, and
D R Abernethy
August 1989,
Journal of clinical microbiology,
J G Niedzwicki, and
K H Mayer, and
E Abushanab, and
D R Abernethy
January 2006,
Archives of internal medicine,
J G Niedzwicki, and
K H Mayer, and
E Abushanab, and
D R Abernethy
February 2003,
Ophthalmology,
J G Niedzwicki, and
K H Mayer, and
E Abushanab, and
D R Abernethy
July 2002,
Clinical and diagnostic laboratory immunology,
